Clinical trials: Adrenocortical Tumor
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Adrenocortical Carcinoma, Adrenocortical Cancer
Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
Background: Adrenocortical cancer (ACC) is a rare tumor. The prognosis is very poor for people with advanced stages of ACC. Some people may live with ACC for years; others live for just months.
- Trial name
- NCT04447014
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Surgery and Heated Chemotherapy for Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare tumor of the adrenal gland. Few people who develop this disease live more than 5 years after being diagnosed.
- Trial name
- NCT01833832
- Testing
- Cisplatin, Cytoreductive surgery, sodium thiosulfate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Primary; Complex, Pigmented Nodular Adrenocortical Disease, Primary, 1
Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)
Cohort CNC-PPNAD will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years. Cohort L-MC will be investigated clinically at inclusion and a PERKAR1A genotype will be performed.
- Conditions
- Primary; Complex, Pigmented Nodular Adrenocortical Disease, Primary, 1, Periorificial Lentiginosis, Cardiac Myxoma
- Trial name
- EVACARNEY (NCT00668291)
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Nonresectable Adrenocortical Carcinoma
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
The use of Iressa will result in a greater than 20% response rate in patients with nonresectable adrenocortical cancer who have previously been treated with one other form of systemic therapy (either Mitotane or chemotherapy).
- Trial name
- NCT00215202
- Testing
- Iressa (ZD1839)
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Pediatric Solid Tumor, Osteosarcoma
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old…
- Conditions
- Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT04897321
- Testing
- Fludarabine, Cyclophosphamide, MESNA
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Adrenal Cortex Neoplasms
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
This study will examine the safety and effectiveness of treating adrenocortical cancer with combination chemotherapy using doxorubicin, vincristine, and etoposide in addition to the drugs mitotane and tariquidar and, when…
- Trial name
- NCT00071058
- Testing
- XR9576 (Tariquidar)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy Trial Type : Single arm, prospective trial Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib) Treatment…
- Trial name
- ACCOMPLISH (NCT05036434)
- Testing
- Pembrolizumab / Lenvatinib
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
This study will evaluate whether the drug mifepristone can improve the symptoms of Cushing's syndrome in people with ectopic adrenal corticotrophin hormone (ACTH) secretion.
- Trial name
- NCT00422201
- Testing
- Mifepristone
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 18 people
- Sponsor
- HRA Pharma
Adrenocortical Carcinoma
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug…
- Trial name
- GALACCTIC (NCT00924989)
- Testing
- OSI-906
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 139 people
- Sponsor
- Astellas Pharma Inc
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Pituitary Adenoma
Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation.
- Trial name
- NCT02574793
- Testing
- continuous glucose monitoring
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Osteogenesis Imperfecta, Osteoporosis
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free…
- Conditions
- Osteogenesis Imperfecta, Osteoporosis, Hypogonadisms, Neoplasia
- Trial name
- NCT07412782
- Testing
- REMS
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Meyer Children's Hospital IRCCS
Adrenal Incidentaloma, Adrenocortical Carcinoma
Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield
Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical…
- Trial name
- SERENDIPITY (NCT02324647)
- Where
- Netherlands
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Adrenal Cortex Neoplasms, Adrenal Cortex Diseases
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
In adrenal tumors, the investigators will examine if there is any correlation between WIESS criteria, prognosis of the tumor, and the different labeling index of the following proliferation biomarkers: MCM3, MCM2, KI-67, P53…
- Trial name
- NCT02747355
- Volunteers
- 70 people
- Sponsor
- Bnai Zion Medical Center
Adrenocortical Carcinoma
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%.
- Trial name
- NCT04318730
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- West China Hospital